Insider Trading at Quest Diagnostics Incorporated?

Bruno Cirelli
Agosto 9, 2017

Finally, Janus Capital Management LLC boosted its position in shares of Quest Diagnostics by 34.2% in the first quarter. PGGM Investments owned approximately 0.15% of Quest Diagnostics worth $22,695,000 at the end of the most recent quarter. Quadrature Capital Ltd bought a new position in Quest Diagnostics during the fourth quarter valued at $1,226,000. Parallel Advisors LLC now owns 1,279 shares of the medical research company's stock worth $137,000 after buying an additional 177 shares during the last quarter. Bank of America Corp DE now owns 1,887,303 shares of the medical research company's stock valued at $185,315,000 after buying an additional 11,399 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Quest Diagnostics during the first quarter valued at $458,000. Teachers Advisors LLC boosted its stake in shares of Quest Diagnostics by 6.6% in the fourth quarter. Chicago Equity Partners LLC now owns 2,700 shares of the medical research company's stock valued at $265,000 after buying an additional 230 shares during the last quarter. Company insiders own 1.50% of the company's stock.

According to Zacks brokerage recommendations, Quest Diagnostics Incorporated (NYSE:DGX)'s Buy count is 1 and Strong Buy is 5 while the number of analysts recommending Sell and Strong Sell are 0 and 11, respectively. Natixis Asset Mngmt accumulated 500 shares or 0% of the stock. The firm has a market cap of $14.58 billion, a PE ratio of 21.54 and a beta of 0.69.

Quest Diagnostics Incorporated (DGX) closed 8.18% above its 200-day moving average and is -2.5% below another chart threshold, its 50-day moving average. Quest Diagnostics has a 12-month low of $79.12 and a 12-month high of $112.96.

Quest Diagnostics Incorporated (NYSE:DGX) soared 15.57% year-to-date. The medical research company reported $1.55 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.42 by $0.13. The firm had revenue of $1.94 billion for the quarter, compared to analysts' expectations of $1.94 billion. Also, the number of funds holding Quest Diagnostics Inc in their top 10 equity positions increased from 3 to 4 for an increase of 1. During the same quarter in the prior year, the business earned $1.34 earnings per share. On average, equities analysts anticipate that Quest Diagnostics Incorporated will post $5.69 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, July 24th. Investec Asset Mngmt North America has 0.19% invested in Quest Diagnostics Inc (NYSE:DGX) for 14,013 shares. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.68%. The ex-dividend date was Thursday, July 6th. Quest Diagnostics's dividend payout ratio (DPR) is now 36.29%.

COPYRIGHT VIOLATION WARNING: This news story was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & global copyright & trademark laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/09/keycorp-comments-on-quest-diagnostics-incorporateds-fy2018-earnings-nysedgx-updated.html. Canaccord Genuity raised their price objective on shares of Quest Diagnostics from $102.00 to $115.00 and gave the stock a "buy" rating in a report on Tuesday, April 25th. ValuEngine upgraded Quest Diagnostics from a "hold" rating to a "buy" rating in a research report on Friday, June 2nd. BidaskClub lowered Quest Diagnostics from a "buy" rating to a "hold" rating in a report on Monday, July 24th. Finally, Barclays PLC reiterated a "hold" rating and set a $110.00 target price on shares of Quest Diagnostics in a report on Wednesday, July 19th. They noted that the move was a valuation call. Quest Diagnostics now has an average rating of "Buy" and a consensus price target of $110.72. About shares traded. Quest Diagnostics Inc (NYSE:DGX) has risen 39.04% since August 8, 2016 and is uptrending. The shares were sold at an average price of $108.73, for a total transaction of $141,783.92. Capstone Asset Management Company acquired 4,634 shares as Quest Diagnostics Inc (DGX)'s stock rose 10.72%. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

In related news, Director Jeffrey M. Leiden sold 1,304 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, July 27th. Following the transaction, the senior vice president now owns 78,582 shares in the company, valued at $8,451,494.10. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock. Wells Fargo upgraded Quest Diagnostics Inc (NYSE:DGX) on Friday, October 16 to "Market Perform" rating. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE